… Other research highlights that RhoA pathway is increased in neurological conditions such
as Alzheimer’s and Huntington’s disease [71, 72], suggesting that a proper RhoA regulation is …

… The SAC halts metaphase to anaphase transition in the presence of unattached and/or
untensed kinetochore(s) by releasing the mitotic checkpoint complex (MCC) from these …

… By a rare combination of intuition and scientific interpretation, this assumption was demonstrated
by Rita Levi-Montalcini, Viktor Hamburger and Stanley Cohen in the early 1950′s with …

… We show here that MutLa modulates Exo1’s activity through a mutual physical interaction,
and depleting MLH1 or disrupting the MLH1-Exo1 interaction allows Exo1 to conduct …

… The mechanisms of therapeutic resistance, often emerging after initial tumour responses,
include (but are not limited to) mutation(s) in the gene encoding the target protein,2 induction of …

Telomerase is an attractive target for anti-tumor therapy as it is almost universally expressed
in cancer cells. Here, we show that treatment with a telomere-targeting drug, 6-thio-2′-…

… Dose response curves were generated and EC 50 s calculated using GraphPad Prism. All
… , and then follow with immune checkpoint inhibitor(s). We do not believe that tyrosine kinase …

G-quadruplex (G4) interacting agents are a class of ligands that can bind to and stabilise
secondary structures located in genomic G-rich regions such as telomeres. Stabilisation of G4 …

… ’s disease (AD), Huntington’s disease (HD), and Parkinson’s disease (PD). Here, we
summarize the current knowledge about the pathophysiological roles of AMPK in regulating …

… Telomere (T) and single copy gene (S) 36B4 were amplified using specific primers with the
Fast SYBR … Relative T/S ratios will reflect relative telomere length as introduced in ref. 16. …